Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 11/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 11/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL733033 | 0.81 | ESR1 (0.34) | CYP19A1ESR1ESR2CYP11B2 | |
| SCHEMBL3465175 | 0.81 | CYP19A1 (0.56) | CYP19A1CYP11B2 | |
| SCHEMBL3464404 | 0.81 | CYP19A1 (0.36) | CYP19A1CYP11B2 | |
| SCHEMBL3466178 | 0.78 | CYP19A1 (0.60) | CYP19A1CYP11B2 | |
| SCHEMBL3464936 | 0.76 | CYP19A1 (0.35) | CYP19A1CYP11B2 | |
| SCHEMBL3465912 | 0.69 | CYP19A1 (0.55) | CYP19A1CYP11B2 | |
| SCHEMBL29646250 | 0.67 | ESR2 (0.53) | ESR1ESR2 | |
| SCHEMBL215429 | 0.67 | ESR2 (0.53) | ESR1ESR2 | |
| SCHEMBL741381 | 0.65 | CYP19A1 (0.48) | CYP19A1CYP11B2 | |
| SCHEMBL743695 | 0.65 | ADRA2A (0.37) | CYP19A1CYP11B2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168145-A1 | FUSED IMIDAZOLE DERIVATIVES AND USE THEREOF AS ALDOSTERONE SYNTHASE INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168145-A1 | FUSED IMIDAZOLE DERIVATIVES AND USE THEREOF AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | CYP19A1 37/4885ESR1 966/4885ESR2 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.